News

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...